No Data
No Data
Moderna Shares Fall 18% After Cutting Annual R&D Spending by $1.1 Billion From 2027
Express News | Moderna : Jefferies Cuts to Hold From Buy
Express News | Moderna : Piper Sandler Cuts Target Price to $115 From $157
Moderna's skin cancer vaccine mRNA-4157 is expected to enter the market as early as 2025.
According to reports, moderna is planning to launch a mRNA-based skin cancer vaccine, mRNA-4157, as early as next year. The vaccine will be used in combination with merck's PD-1 therapy Keytruda for the treatment of melanoma.
S&P 500, Nasdaq Jump For 4th Straight Day As Tech Leads Stocks Higher
CSL Competitor Moderna Shifts Flu Vaccine Strategy -- Market Talk